Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient (Q37204444)

18 August 2017

1 reference

title

Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient (English)

1 reference

18 August 2017

1 reference

1 reference

Kathleen W Beekman

1

1 reference

PubMed ID

18593620

18 August 2017

Maha Hussain

series ordinal

2

1 reference

18 August 2017

1 July 2008

1 reference

18 August 2017

1 reference

18 August 2017

26

1 reference

18 August 2017

4

1 reference

18 August 2017

415-419

1 reference

Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Combined finasteride and flutamide therapy in men with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.003

10.1016/J.UROLONC.2007.11.003

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18593620